Abstract
The risk assessment process is described with a focus on the hazard identification and dose-response components. Many of the scientific questions and uncertainties associated with these components are discussed, and the role for biomarkers and specimen banking in supporting these activities are assessed. Under hazard identification, the use of biomarkers in defining and predicting a) biologically adverse events; b) the progression of those events towards disease; and c) the potential for reversibility are explored. Biomarker applications to address high-to-low dose extrapolation and interindividual variability are covered under dose-response assessment. Several potential applications for specimen banking are proposed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bender A. P., Williams A. N., Johnson R. A., Jagger H. G. Appropriate public health responses to clusters: the art of being responsibly responsive. Am J Epidemiol. 1990 Jul;132(1 Suppl):S48–S52. doi: 10.1093/oxfordjournals.aje.a115788. [DOI] [PubMed] [Google Scholar]
- Griffith J., Duncan R. C., Hulka B. S. Biochemical and biological markers: implications for epidemiologic studies. Arch Environ Health. 1989 Nov-Dec;44(6):375–381. doi: 10.1080/00039896.1989.9935910. [DOI] [PubMed] [Google Scholar]
- Henderson R. F., Bechtold W. E., Bond J. A., Sun J. D. The use of biological markers in toxicology. Crit Rev Toxicol. 1989;20(2):65–82. doi: 10.3109/10408448909017904. [DOI] [PubMed] [Google Scholar]